Erivedge(vismodegib)
Erivedge (vismodegib) is a small molecule pharmaceutical. Vismodegib was first approved as Erivedge on 2012-01-30. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell carcinoma. The pharmaceutical is active against smoothened homolog.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Erivedge
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vismodegib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ERIVEDGE | Genentech | N-203388 RX | 2012-01-30 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| erivedge | New Drug Application | 2020-08-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| skin neoplasms | EFO_0004198 | D012878 | C44 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
81 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Basal cell neoplasms | D018295 | 2 | 13 | — | 2 | 4 | 21 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 4 | 7 | — | — | 1 | 11 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 5 | 4 | — | — | — | 8 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | — | — | — | 5 |
| Medulloblastoma | D008527 | 2 | 4 | — | — | — | 5 | ||
| Prostatic neoplasms | D011471 | C61 | 3 | 2 | — | — | — | 4 | |
| Multiple myeloma | D009101 | C90.0 | 2 | 2 | — | — | — | 4 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 4 | — | — | — | 4 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 2 | — | — | 1 | 4 |
| Basal cell nevus syndrome | D001478 | EFO_0004136 | — | 3 | — | — | 1 | 4 | |
| Colorectal neoplasms | D015179 | — | 3 | — | — | — | 3 |
Show 49 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Primary myelofibrosis | D055728 | D47.4 | 2 | — | — | — | — | 2 | |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 | ||
| Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | — | — | — | — | 1 | |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VISMODEGIB |
| INN | vismodegib |
| Description | Vismodegib is a benzamide obtained by formal condensation between the carboxy group of 2-chloro-4-(methylsulfonyl)benzoic acid and the anilino group of 4-chloro-3-(pyridin-2-yl)aniline. Used for the treatment metastatic basal cell carcinoma. It has a role as an antineoplastic agent, a SMO receptor antagonist, a Hedgehog signaling pathway inhibitor and a teratogenic agent. It is a sulfone, a member of benzamides, a member of pyridines and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | hedgehog signaling inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1 |
Identifiers
| PDB | 5L7I |
| CAS-ID | 879085-55-9 |
| RxCUI | 1242987 |
| ChEMBL ID | CHEMBL473417 |
| ChEBI ID | 66903 |
| PubChem CID | 24776445 |
| DrugBank | DB08828 |
| UNII ID | 25X868M3DS (ChemIDplus, GSRS) |
Target
Agency Approved
SMO
SMO
Organism
Homo sapiens
Gene name
SMO
Gene synonyms
SMOH
NCBI Gene ID
Protein name
smoothened homolog
Protein synonyms
frizzled family member 11, Protein Gx, seven transmembrane helix receptor, smoothened, frizzled family receptor, smoothened, seven transmembrane spanning receptor
Uniprot ID
Mouse ortholog
Smo (319757)
smoothened homolog (P56726)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Erivedge - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,387 documents
View more details
Safety
Black-box Warning
Black-box warning for: Erivedge
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more